Immunogenicity and protective efficacy of a recombinant subunit West Nile Virus vaccine in rhesus monkeys

Michael M. Lieberman, Vivek R. Nerurkar, Haiyan Luo, Bruce Cropp, Ricardo Carrion, Melissa De La Garza, Beth Ann Coller, David Clements, Steven Ogata, Teri Wong, Tim Martyak, Carolyn Weeks-Levy

    Research output: Contribution to journalArticlepeer-review

    56 Scopus citations

    Abstract

    The immunogenicity and protective efficacy of a recombinant subunit West Nile virus (WNV) vaccine was evaluated in rhesus macaques (Macaca mulatta). The vaccine consisted of a recombinant envelope (E) protein truncated at the C-terminal end, resulting in a polypeptide containing 80% of the N-terminal amino acids of the native WNV protein (WN-80E), mixed with an adjuvant (GPI-0100). WN-80E was produced in a Drosophila melanogaster expression system with high yield and purified by immunoaffinity chromatography using a monoclonal antibody specific for flavivirus E proteins. Groups of monkeys were vaccinated with formulations containing 1 or 25 μg of WN-80E antigen, and both humoral and cellular immunity were assessed after vaccination. The results demonstrated potent antibody responses to vaccination, as determined by both enzyme-linked immunosorbent assay and virus-neutralizing antibody assays. All vaccinated animals responded favorably, and there was little difference in response between animals immunized with 1 or 25 μg of WN-80E. Cellular immunity was determined by lymphocyte proliferation and cytokine production assays using peripheral blood mononuclear cells from vaccinated animals stimulated in vitro with WN-80E. Cell-mediated immune responses varied from animal to animal within each group. About half of the animals responded with lymphoproliferation, cytokine production, or both. Again, there was little difference in response between animals immunized with a 1- or 25-μg dose of WN-80E in the vaccine formulations. In a separate experiment, groups of monkeys were immunized with the WN-80E/GPI-0100 vaccine or an adjuvant-only control formulation. Animals were then challenged by inoculation of wild-type WNV, and the level of viremia in each animal was monitored daily for 10 days. The results showed that whereas all animals in the control group had detectable viremia for at least 3 days after challenge, all of the vaccinated animals were negative on all days after challenge. Thus, the WN-80E vaccine was 100% efficacious in protecting monkeys against infection with WNV.

    Original languageEnglish (US)
    Pages (from-to)1332-1337
    Number of pages6
    JournalClinical and Vaccine Immunology
    Volume16
    Issue number9
    DOIs
    StatePublished - Sep 2009

    ASJC Scopus subject areas

    • Immunology and Allergy
    • Immunology
    • Clinical Biochemistry
    • Microbiology (medical)

    Fingerprint Dive into the research topics of 'Immunogenicity and protective efficacy of a recombinant subunit West Nile Virus vaccine in rhesus monkeys'. Together they form a unique fingerprint.

    Cite this